Table 4 Response rates of salvage chemotherapy for recurrent or refractory clear cell carcinoma
From: Clear cell carcinoma of the ovary: Is there a role of histology-specific treatment?
regimen | author | year | response/ number of patients, response rate |
|---|---|---|---|
Megestrol acetate | Walailak [45] | 2001 | 2/10, 20% |
Cyclopshosphamide+cisplatin | Takano [46] | 2008 | 1/9, 11% |
Irinotecan+Platinum | Sugiyama [29] | 1998 | 1/3, 33% |
Takano [46] | 2008 | 2/15, 13% | |
Etoposide+Platinum | Takano [46] | 2008 | 2/13, 15% |
Paclitaxel+Carboplatin | Utsunomiya [32] | 2006 | 3/13, 23% |
Crotzer [43] | 2007 | 2/7, 29% | |
Gemcitbine | Crotzer [43] | 2007 | 1/9, 11% |
Yoshino [47] | 2012 | 1/5, 20% | |
Docetaxel+Irinotecan | Yoshino [47] | 2012 | 1/11, 9% |
Temsirolimus | Takano [46] | 2011 | 1/5, 20% |